Business Wire

NY-IFF

Share
IFF Recognized by EDGE for Commitment to Workplace Diversity

IFF (NYSE: IFF) today announced that EDGE—the leading global assessment and business certification for gender and intersectional equity—has recertified the company as EDGE Move level globally. The marks the first—and currently the only—time a company has earned this level of recognition twice. The company also added an EDGEplus to its certification for its commitment to broader workplace diversity and intersectional issues. The assessment encompassed 27 countries, giving IFF the distinction of having the largest number of EDGE-certified countries at one time.

Earning certification entails a rigorous third-party review of gender representation, pay equity, the effectiveness of policies and practices and the inclusiveness of an organization’s culture. As part of the assessment, a global survey is also distributed to employees to gauge perception of gender equity in the workplace.

“We’re very proud of this achievement, especially because it follows our team doubling in size after our 2021 merger,” said Frank Clyburn, CEO, IFF. “But even as we celebrate this recognition, we focus on the opportunities that EDGE has identified to help make IFF a fairer and more inclusive workplace, achieving greater gender parity and representation across our global footprint. Our team is fully committed to furthering our progress.”

“In 2020, IFF was the first company to be globally certified at the EDGE Move level, and today’s announcement is another first,” said Aniela Unguresan, founder, EDGE Certified Foundation. “IFF’s achievements demonstrate that putting gender and intersectional equity at the heart of their business leads to visible and credible progress.”

Women at IFF represent 36.4% of leadership, with no statistically relevant gender pay gap in favor of men in any of the 27 assessed countries. In 2022, the Company advanced efforts to create a fairer and more inclusive place to work. This includes introducing a Global Parental Leave policy, which provides a minimum of 16 weeks paid leave for all new or continuing parents following the birth, surrogacy or adoption of a child. The Company has also expanded the size and scope of activities of the Women@IFF employee resource group.

“At IFF, we live out our deep commitment to diversity, equity and inclusion, embedding practices and policies that support gender and intersectional equity,” said Deborah Borg, IFF chief human resources officer and chief diversity & inclusion officer. “Through assessments like EDGE and the guidance they provide, we can measure our progress and take intentional, measured steps to impact workforce representation, and ensure IFF remains a great place to work.”

Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.

© 2022 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005790/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release

Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/

Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia17.10.2025 14:15:00 CEST | Press release

Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP’s opinion, with the final decision expected by early 2026 PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, pending European Commission approval Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for t

Kinaxis Accelerates Agentic Era for Supply Chain Orchestration with the Launch of Maestro Agents17.10.2025 13:00:00 CEST | Press release

AI agents that plan with you, not just for you, empower the customer journey to a next generation of the adaptive supply chain Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy. “Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.” Maestro Agents advance the customer journe

SLB Announces Third-Quarter 2025 Results17.10.2025 12:50:00 CEST | Press release

Revenue of $8.93 billion increased 4% sequentially and decreased 3% year on year GAAP EPS of $0.50 decreased 32% sequentially and 40% year on year EPS, excluding charges and credits, of $0.69 decreased 7% sequentially and 22% year on year Net income attributable to SLB of $739 million decreased 27% sequentially and 38% year on year Adjusted EBITDA of $2.06 billion was flat sequentially and decreased 12% year on year Cash flow from operations was $1.68 billion and free cash flow was $1.10 billion, including $153 million of acquisition-related payments Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the third-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015948706/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2025Jun. 30, 2025Sept. 30, 2024Se

Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program17.10.2025 02:42:00 CEST | Press release

One of just nine voucher recipients chosen and the only one in the eye space, the selection spotlights Dompé’s dedication to accelerate innovation and deliver breakthrough therapies to patients who urgently need them.With this selection, Dompé receives a voucher shortening the marketing application review from the standard 10–12 months to just 1–2 months.Dompé plans to apply the voucher to its Biologics License Application (BLA) for an intranasal form of Nerve Growth Factor (Cenegermin-bkbj) for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and the US, announced today its selection by the United States Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of its select

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye